Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H27NO2 |
| Molecular Weight | 373.4874 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1OC2CCCC2)[C@H](CC3=CC=NC=C3)C4=CC=CC=C4
InChI
InChIKey=UTUUPXBCDMQYRR-HSZRJFAPSA-N
InChI=1S/C25H27NO2/c1-27-24-12-11-21(18-25(24)28-22-9-5-6-10-22)23(20-7-3-2-4-8-20)17-19-13-15-26-16-14-19/h2-4,7-8,11-16,18,22-23H,5-6,9-10,17H2,1H3/t23-/m1/s1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16168647 | https://www.ncbi.nlm.nih.gov/pubmed/24904269
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16168647 | https://www.ncbi.nlm.nih.gov/pubmed/24904269
CDP 840 hydrochloride is a potent and selective inhibitor of phosphodiesterase 4 (PDE4). This compound competitively inhibits all PDE4 isoenzymes, which in turn prevents the cleavage of phosphodiester bonds found in secondary messenger molecules. CDP-840 had been in phase II clinical trials for the treatment of asthma. However, CDP840 did not lead to changes in baseline forced expiratory volume in one second (FEV1) as compared to placebo. CDP 840 research has been discontinued.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL254 |
2.1 nM [IC50] | ||
Target ID: CHEMBL291 |
4.5 nM [IC50] | ||
Target ID: CHEMBL288 |
2.1 nM [IC50] | ||
Target ID: CHEMBL275 |
1.4 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor. | 1996 Jul |
|
| Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. | 2005 Dec 1 |
Patents
Sample Use Guides
Patients were allocated either 15 mg b.i.d. CDP840
or placebo for a period of 9.5 days.
Route of Administration:
Oral
Incubations with microsomes prepared from different species were typically conducted under linear conditions with 80 mkM CDP-840 and 0.5 mg of microsomal protein in the presence of an NADPH-generating system. Incubations (0.5 ml) were conducted for 30 min at 37°C and were quenched by the addition of an equal volume of acetonitrile.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60936715
Created by
admin on Sat Dec 16 17:06:21 GMT 2023 , Edited by admin on Sat Dec 16 17:06:21 GMT 2023
|
PRIMARY | |||
|
OK8OFX8K7F
Created by
admin on Sat Dec 16 17:06:21 GMT 2023 , Edited by admin on Sat Dec 16 17:06:21 GMT 2023
|
PRIMARY | |||
|
162542-90-7
Created by
admin on Sat Dec 16 17:06:21 GMT 2023 , Edited by admin on Sat Dec 16 17:06:21 GMT 2023
|
PRIMARY | |||
|
127928
Created by
admin on Sat Dec 16 17:06:21 GMT 2023 , Edited by admin on Sat Dec 16 17:06:21 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
